{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:57:25Z","timestamp":1761631045497,"version":"3.40.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T00:00:00Z","timestamp":1699056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.dld.2023.10.027","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:59:03Z","timestamp":1700269143000},"page":"737-743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9009-9635","authenticated-orcid":false,"given":"Paula","family":"Sousa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Patita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Arroja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Lago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2953-5987","authenticated-orcid":false,"given":"Isadora","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena Tavares","family":"de Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Ministro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Mocanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Castela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Moleiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Roseira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Cancela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Portela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Correia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mafalda","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Afonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia Camila","family":"Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2023.10.027_bib0001","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/apt.16785","article-title":"Review article: emerging drug therapies in inflammatory bowel disease","volume":"55","author":"Grossberg","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2023.10.027_bib0002","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1136\/gutjnl-2020-322646","article-title":"Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn's disease","volume":"70","author":"Verstockt","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.dld.2023.10.027_bib0003","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/gutjnl-2019-320185","article-title":"Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11\u2009928 patients in the UK inflammatory bowel disease bioresource","volume":"70","author":"Stournaras","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.dld.2023.10.027_bib0004","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/apt.17128","article-title":"Classic drugs in the time of new drugs: real-world, long-term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease","volume":"56","author":"Rezazadeh Ardabili","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2023.10.027_bib0005","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.dld.2023.10.027_bib0006","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"14","author":"Torres","year":"2019","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.dld.2023.10.027_bib0007","article-title":"Upfront combination therapy, compared with monotherapy, for patients not previously treated with a biologic agent associates with reduced risk of inflammatory bowel disease-related complications in a population-based cohort study","volume":"17","author":"Targownik","year":"2019","journal-title":"Clinic Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2023.10.027_bib0008","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2023.10.027_bib0009","article-title":"Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease","volume":"5","author":"Boyapati","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.dld.2023.10.027_bib0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2468-1253(22)00385-5","article-title":"Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial","volume":"8","author":"Louis","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2023.10.027_bib0011","article-title":"Predicting, preventing, and managing treatment-related complications in patients with inflammatory bowel diseases","volume":"18","author":"Beaugerie","year":"2020","journal-title":"Clinic Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2023.10.027_bib0012","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/apt.13001","article-title":"A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity","volume":"41","author":"Khanna","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2023.10.027_bib0013","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820965790","article-title":"Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays","volume":"13","author":"Rocha","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.dld.2023.10.027_bib0014","article-title":"Histologic Features of Colon Biopsies (Geboes Score) associated with progression of ulcerative colitis for the first 36 months after biopsy","volume":"19","author":"Magro","year":"2021","journal-title":"Clinic Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2023.10.027_bib0015","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/ecco-jcc\/jjy168","article-title":"Development and validation of risk matrices concerning ulcerative colitis outcomes-Bayesian network analysis","volume":"13","author":"Magro","year":"2019","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.dld.2023.10.027_bib0016","article-title":"Subclinical persistent inflammation as risk factor for Crohn's disease progression: findings from a prospective real-world study of 2 years","volume":"20","author":"Magro","year":"2022","journal-title":"Clinic Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2023.10.027_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2020.07.008","article-title":"Duration of combination therapy and risk of treatment failure in patients with inflammatory bowel disease","volume":"45","author":"Lambrescak","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.dld.2023.10.027_bib0018","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1038\/ajg.2009.301","article-title":"Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis","volume":"104","author":"Peyrin-Biroulet","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2023.10.027_bib0019","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.dld.2021.05.038","article-title":"Thiopurines: use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease","volume":"53","author":"Sousa","year":"2021","journal-title":"Digest Liver Dis"},{"key":"10.1016\/j.dld.2023.10.027_bib0020","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/gutjnl-2013-305259","article-title":"The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab","volume":"63","author":"Ungar","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.dld.2023.10.027_bib0021","article-title":"Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis","volume":"17","author":"Colombel","year":"2019","journal-title":"Clinic Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2023.10.027_bib0022","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2023.10.027_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102832","article-title":"Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy","volume":"20","author":"Privitera","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.dld.2023.10.027_bib0024","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/apt.16050","article-title":"Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and\/or thiopurines in patients with inflammatory bowel disease","volume":"52","author":"Chupin","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2023.10.027_bib0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ecco-jcc\/jjx101","article-title":"European Crohn's and colitis organisation topical review on treatment withdrawal ['exit strategies'] in inflammatory bowel disease","volume":"12","author":"Doherty","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2023.10.027_bib0026","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjad001","article-title":"ECCO topical review on biological treatment cycles in Crohn's disease","author":"Noor","year":"2023","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.dld.2023.10.027_bib0027","article-title":"Optimizing anti-TNF-\u03b1 therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases","volume":"14","author":"Ungar","year":"2016","journal-title":"Clinic Gastroenterol Hepatol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865823010162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865823010162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T10:28:43Z","timestamp":1729160923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865823010162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1590865823010162"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2023.10.027","relation":{},"ISSN":["1590-8658"],"issn-type":[{"type":"print","value":"1590-8658"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2023.10.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}